13G Filing: Sabby Capital and Arca Biopharma Inc. (ABIO)
Sabby Healthcare Master Fund, Ltd | 0 | 446,052 | 0 | 446,052 | 446,052 | 3.80 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 00211Y407 1.
Arca Biopharma Inc. (ABIO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 1,200,000 | $4,596,000 | 0% | |
| 2. | Avidity Partners Management David Witzke And Michael Gregory | 1,000,000 | $3,830,000 | 0.16% | |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 414,325 | $1,586,865 | 0.1% | |
| 4. | ADAR1 Capital Management Daniel Schneeberger | 84,676 | $324,309 | 0.06% | |
| 5. | Renaissance Technologies Jim Simons | 73,099 | $279,969 | +12% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.98 | 428 | Large Shareholder | 2,117,213 | 2024-08-16 | Filing | |
| $2.93 | 5,390 | Large Shareholder | 2,116,785 | 2024-08-16 | Filing | |
| $3.05 | 30,227 | Large Shareholder | 2,111,395 | 2024-07-25 | Filing | |
| $3.16 | 7,056 | Large Shareholder | 2,081,168 | 2024-07-24 | Filing | |
| $3.18 | 17,800 | Large Shareholder | 2,074,112 | 2024-07-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.50 | 482 | Officer | 13,153 | 2018-04-03 | Filing | |
| $0.50 | 1,114 | Officer | 0 | 2018-04-02 | Filing | |
| $0.72 | 410 | Officer | 13,635 | 2018-02-28 | Filing | |
| $0.53 | 161 | Officer | 1,114 | 2018-02-27 | Filing | |
| $0.53 | 41,331 | Large Shareholder | 0 | 2018-02-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,000,452 | $6,800,768 | 7.06% | |
| 2. | 1,410,143 | $2,397,243 | 1.59% | |
| 3. | 706,930 | $1,201,781 | 0.91% | |
| 4. | 453,598 | $771,117 | 0% | |
| 5. | 231,911 | $394,249 | 0% |
News See All
Venrock's Latest Pick Shows There Are More Biotech Opportunities to Explore
Biotech is a hot segment right now and even though it has many opportunities, it is also associated with a lot of risks.
RA Capital Is Expecting A Breakthrough Cardiovascular Drug From This Biotech
The biotechnology industry is up by more than 50% over the last year, but these towering returns don't come without great risk and volatility.
Billionaire Hedge Funds
